Nuwellis Announces Preliminary Revenue Results for the Second Quarter 2026 Showing Double Digit Growth

Nuwellis (Nasdaq: NUWE) released unaudited preliminary results for the quarter ended June 30, 2026, expecting 14% year-over-year revenue growth for the second quarter and 20% growth for the first six months of 2026.

Rhea-AI Summary

Nuwellis (Nasdaq: NUWE) released unaudited preliminary results for the quarter ended June 30, 2026, expecting 14% year-over-year revenue growth for the second quarter and 20% growth for the first six months of 2026. Management attributes this performance to continued commercial momentum and increasing adoption of the Aquadex Ultrafiltration platform.

According to Nuwellis, final second-quarter and first-half 2026 financial results will be reported on August 13, 2026, before the U.S. market open, followed by a conference call and webcast at 9:00 a.m. Eastern time.

Positive

• Preliminary Q2 2026 revenue growth of 14% year over year
• Preliminary first-half 2026 revenue growth of 20% year over year
• Management reports continued commercial momentum for the Aquadex Ultrafiltration platform

Negative

• None.

Argus Jul 27 session 8 alerts

-2.93% close to close 0.2x rel. volume Open Argus

Details

News Market Reaction – NUWE

+7.7% Peak Tracked

-5.6% Trough Tracked

$199,460 Market Cap

In the Jul 27 session, NUWE declined 2.93%, reflecting a moderate negative market reaction. Argus tracked a peak move of +7.7% during that session. Argus tracked a trough of -5.6% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

NUWE has an active, effective S-3 resale registration dated February 3, 2026. That platform record a...

Analysis

NUWE has an active, effective S-3 resale registration dated February 3, 2026. That platform record adds capital-structure context: Nuwellis will not sell shares directly or receive proceeds from stockholder resales; the preliminary growth remains unaudited.

Key Figures

Q2 revenue growth: 14% First-half revenue growth: 20% Financial results date: August 13, 2026

Q2 revenue growth

14%

Year-over-year, second quarter 2026 preliminary results

First-half revenue growth

20%

Year-over-year, first six months of 2026 preliminary results

Financial results date

August 13, 2026

Scheduled reporting date for the three and six months ended June 30, 2026

Previous Earnings Reports

5 past events · Latest: May 12

Same Type 5 events

1. May 12

   Q1 earnings report

   24h Move

   -1.0%

   Revenue and gross margin improved, but the 24-hour reaction was -0.96%.

2. Mar 10

   Q4 earnings report

   24h Move

   +0.8%

   Full-year revenue declined and losses continued, while the 24-hour reaction was +0.78%.

3. Nov 12

   Q3 earnings report

   24h Move

   -4.0%

   Quarterly revenue declined and operating losses increased, followed by a -3.96% reaction.

4. Aug 14

   Q2 earnings report

   24h Move

   +2.5%

   Revenue and gross margin declined, while the 24-hour reaction was +2.55%.

5. May 13

   Q1 earnings report

   24h Move

   +0.9%

   Revenue and pediatric revenue increased, followed by a +0.91% reaction.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

ultrafiltration, cardiorenal, form 10-q

3 terms

ultrafiltration medical

"as Aquadex Ultrafiltration platform drives continued commercial momentum"

Ultrafiltration is a process that separates small particles and liquids from larger molecules or substances using a filter with tiny pores. It is often used in water treatment and medical applications to remove impurities or excess fluids. For investors, understanding ultrafiltration is important because innovations or changes in this technology can impact industries focused on clean water, healthcare, and filtration products.

cardiorenal medical

"solutions for patients with cardiorenal conditions"

Cardiorenal describes the close connection between the heart and kidneys, including conditions where disease in one organ directly affects the other — like a pump and filter that rely on each other to keep the system balanced. Investors care because treatments, diagnostics, or drugs that target this interaction can address multiple health problems at once, influencing market size, regulatory scrutiny, clinical trial complexity, and potential returns in healthcare and biotech sectors.

form 10-q regulatory

"filed with the Company’s Quarterly Report on Form 10-Q"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company expects preliminary revenue year-over-year growth of 14% for second quarter 2026 and 20% for the first half of 2026 as Aquadex Ultrafiltration platform drives continued commercial momentum

Nuwellis to report second quarter 2026 financial results on August 13

MINNEAPOLIS, July 27, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced unaudited preliminary results for its second quarter ended June 30, 2026, with revenue year-over-year growth of 14% for the second quarter of 2026 and 20% for the first six months of 2026. Management expects to report its financial results for the three and six months ended June 30, 2026, before the open of the U.S. financial markets on August 13^th and will host a conference call and webcast beginning at 9:00 a.m. Eastern time.

"Our second quarter preliminary revenue results reflect continued commercial momentum and the outstanding execution of our entire Nuwellis team," said Mike McCormick, Nuwellis Chief Executive Officer. "Revenue growth of 20% during the first half of 2026 demonstrates the increasing adoption of Aquadex and the progress we are making in executing our long-term growth strategy. During our earnings call, we look forward to reviewing our financial performance, and discussing our commercial initiatives, product development programs, and strategic partnerships. Additionally, we will highlight opportunities we believe position us for continued growth through the remainder of 2026 and into next year."

The financial information in this release is unaudited and subject to adjustment and confirmation as the Company completes its quarterly review and finalizes its financial statements to be filed with the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and discussed in greater detail during its financial results conference call.

Conference Call & Webcast Information

Date: August 13, 2026
Time: 9:00 a.m. Eastern Time
Dial-in: 1-833-316-1983 or 1-785-838-9310
Conference ID: NUWEQ2

To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com or access here. An audio archive of the webcast will be available following the call on the Investors page.

About Aquadex
The Aquadex SmartFlow System is indicated for the continuous ultrafiltration therapy for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a healthcare provider, within an outpatient or inpatient clinical setting, under physician prescription, both of whom having received training in extracorporeal therapies.

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations. For more information, visit www.nuwellis.com.

Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.

For further information, please contact:

Investor Relations:
CORE IR
ir@nuwellis.com

Media Contact:
CORE PR
media@nuwellis.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What preliminary revenue growth did Nuwellis (NUWE) report for Q2 2026?

Nuwellis expects preliminary Q2 2026 revenue growth of 14% year over year. According to Nuwellis, this unaudited figure reflects continued commercial momentum driven by increasing adoption of its Aquadex Ultrafiltration platform and will be finalized with the Form 10-Q filing.

How did Nuwellis (NUWE) perform in the first half of 2026 in terms of revenue?

Nuwellis expects revenue for the first six months of 2026 to grow 20% year over year. According to Nuwellis, this unaudited preliminary growth demonstrates broader adoption of Aquadex and alignment with the company’s long-term commercial strategy for its cardiorenal solutions.

When will Nuwellis (NUWE) report its final Q2 2026 financial results?

Nuwellis plans to report final Q2 and first-half 2026 results on August 13, 2026. According to Nuwellis, the release will occur before the U.S. market opens, followed by a conference call and webcast at 9:00 a.m. Eastern time for investors.

What is driving Nuwellis (NUWE) revenue growth in early 2026?

Nuwellis attributes its early 2026 revenue growth to the Aquadex Ultrafiltration platform. According to Nuwellis, increasing adoption of Aquadex is supporting 14% Q2 and 20% first-half 2026 preliminary year-over-year revenue growth and aligns with its long-term growth strategy.

How can investors access the Nuwellis (NUWE) Q2 2026 earnings call and webcast?

Investors can access the Q2 2026 call via dial-in or webcast on August 13, 2026. According to Nuwellis, dial-in numbers are 1-833-316-1983 and 1-785-838-9310, with conference ID NUWEQ2, and a webcast and archive will be on the Investors page.

Are Nuwellis (NUWE) Q2 2026 financial figures final or preliminary?

The Q2 and first-half 2026 figures released by Nuwellis are unaudited and preliminary. According to Nuwellis, these numbers remain subject to adjustment and confirmation as the company completes its quarterly review and files its Form 10-Q for the period.